Colin Barnes

Colin is an experienced patent attorney who has worked with Nuclera for several years as outside counsel, writing many of Nuclera’s patents, before joining in 2022.  Colin has nearly 25 years’ experience working with global biotechnology companies.  Colin was the first employee of DNA sequencing company Solexa and is an inventor on over 50 granted EP and US patents on the methodology as practiced by Illumina.  Colin has a PhD in nucleic acid chemistry from the Institute of Cancer Research in London.